Phase 1 Start~month

Phase 1 Start: A Multi-center, Open-label, Phase I Study Evaluating Safety, Tolerability, Pharmacokinetics and Anti

Name: Phase 1 Start: A Multi-center, Open-label, Phase I Study Evaluating Safety, Tolerability, Pharmacokinetics and Anti
Start: 2026-09-23
End: 2026-09-23

September 23, 2026

ANL overview →Track this catalyst

Company: Adlai Nortye Ltd. (ANL)
Indication: RAS Mutation; Solid Tumor (Phase I); CEACAM5

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 1 Start: A Multi-center, Open-label, Phase I Study Evaluating Safety, Tolerability, Pharmacokinetics and Anti — ANL Phase 1 Start | BioSniper